Can ozone gas ease Chemo's lasting numbness?
NCT ID NCT06706544
First seen Sep 18, 2026 · Last updated Sep 18, 2026
Summary
Researchers test whether adding rectal ozone therapy to usual care can reduce numbness and tingling in people with chemotherapy-induced peripheral neuropathy. The trial enrolls 42 adults whose cancer is stable or in remission and who have had persistent numbness or tingling for at least three months. Participants receive 40 rectal gas treatments over 16 weeks, either ozone or oxygen as a placebo, and answer questionnaires about symptoms, quality of life, and mood before, after, and 12 weeks later.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ozone therapy given as a gas mixture through the rectum
- What this could lead to
- If it works, ozone therapy could become an added option to ease persistent numbness and tingling after chemotherapy and improve daily quality of life.
- What could go wrong
- This is a small trial of 42 people, so results may not hold in larger groups. Rectal gas insufflation can cause discomfort, and ozone therapy is not proven for this use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 42 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Mar 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. Adults \> = 18 years old. * 2\. Previous treatment with any chemotherapy because of any tumor. * 3\. Clinical diagnosis of paresthesia (numbness, tingling) secondary to CIPN, with toxicity Grade \> = 2 (according to the Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute of EEUU, v.5.0) for \> = 3 months. * 4\. Without neurotoxic chemotherapy \> = 3 months. * 5\. Cancer disease is stable or in remission. * 6\. Life expectancy \> = 6 months. * 7\. Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit and accept the use of appropriate contraceptive methods at least from 14 days before the first ozone therapy session up to 14 days after the last one. * 8\. To sign and date the study-specific informed consent Exclusion Criteria: * 1\. Age \< 18 years. * 2\. A woman who is lactating, pregnant, suspected of being pregnant, or a woman of childbearing potential who does not use adequate contraceptive methods. * 3\. Suspected symptoms are due to diabetic or compressive neuropathy. * 4\. Severe psychiatric disorders. * 5\. Inability to complete the quality of life questionnaires. * 6\. Elevation above 5 times the maximum limit of normal creatinine. * 7\. Patient who is hemodynamic or clinically unstable or who requires urgent or short-term interventional measures. * 8\. Neoplasia in progression requiring recent initiation of systemic treatment or maintenance with neurotoxic chemotherapy. * 9\. Life expectancy (for any reason) \< 6 months. * 10\. Known allergy to ozone, known glucose 6 phosphate dehydrogenase (G6PD) deficiency, or hemochromatosis. * 11\. Contraindications or impossibility for rectal ozone treatment or to attend regularly to the treatment. * 12\. Not meeting each and every one of the inclusion criteria
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chemotherapy induced peripheral neuropathy (CIPN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Dr. Negrín University Hospital
RECRUITINGLas Palmas, Las Palmas, 35019, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massage gun vs. hands: which eases Post-Hip-Surgery numbness?
- Chilling out Chemo's side effects: could cold therapy shield nerves?
- Could simple exercises rebuild strength after chemotherapy nerve damage?
- Acupuncture vs. sham needles: a test for chemo nerve damage
- Video analysis could personalize rehab for chemo nerve damage
- Brain training and nerve stretching could ease chemo nerve damage